Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Scientists showcase HDL nanotherapy that may provide solution to repeat heart attacks

Up to 30 percent of heart attack patients suffer a new heart attack because cardiologists are unable to control inflammation inside heart arteries - the process that leads to clots rupturing and causing myocardial infarction or stroke.

22 Jan 2014

Home blood pressure best guide to metabolic risk

Home blood pressure is a good guide to which patients are likely to have the metabolic syndrome, say researchers.

20 Jan 2014

New technology may provide solution to high risk of repeat heart attacks, say scientists

Up to 30 percent of heart attack patients suffer a new heart attack because cardiologists are unable to control inflammation inside heart arteries — the process that leads to clots rupturing and causing myocardial infarction or stroke.

20 Jan 2014

People who decrease sitting time and increase physical activity have lower risk of chronic disease

People who decrease sitting time and increase physical activity have a lower risk of chronic disease, according to Kansas State University research.

16 Jan 2014

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

PAZ extracts may be useful option for improving plasma cholesterol profile

Health Enhancement Products, Inc., in conjunction with Wayne State University's Department of Nutrition and Food Science in the College of Liberal Arts and Sciences, announces the publication of a scientific article in the Journal of Nutrition & Metabolism, "ProAlgaZyme sub-fraction improves the lipoprotein profile of hypercholesterolemic hamsters, while inhibiting production of betaine, carnitine, and choline metabolites."

22 Dec 2013

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

Potential dual benefits to tackling LUTS progression risk factors

Research shows that several risk factors associated with Type 2 diabetes and cardiovascular disease also predict the progression of storage and voiding lower urinary tract symptoms in men, suggesting that targeting these could have multiple benefits.

16 Dec 2013

Researchers identify central switch by which HDL controls inflammatory response

High-density lipoprotein, known colloquially as "good cholesterol", protects against dangerous deposits in the arteries. An important function of HDL is its anti-inflammatory properties. An international research team at the Institute of Innate Immunity at the University Hospital of Bonn and the LIMES Institute at the University of Bonn has identified a central switch by which HDL controls the inflammatory response. The results are presented in the current issue of "Nature Immunology".

9 Dec 2013

Sinai Hospital reports results from Phase 2a trial of apo A-I infusion therapy CSL112

Researchers from the Sinai Center for Thrombosis Research presented findings from a Phase 2a trial substudy that examined the antiplatelet effects of CSL112, a novel apolipoprotein A-I (apo A-I) infusion therapy, at the American Heart Association 2013 Scientific Sessions.

22 Nov 2013

Simple blood test may predict people at highest risk for developing heart problems

For years, doctors have been divided on how effective annual testing and screenings are for apparently healthy individuals. New research, however, shows that a simple blood test may predict who is at highest risk to develop heart problems - and how long these people may have to live.

20 Nov 2013

Patients better adhere to medication regimens following hospitalization for acute coronary syndrome

Patients better adhered to their medication regimens in the year following hospitalization for acute coronary syndrome when they were part of a program that included personalized attention from a pharmacist compared with usual care, according to a study by P. Michael Ho, M.D., Ph.D., of the Denver VA Medical Center, and colleagues.

19 Nov 2013

Researchers develop more accurate way to calculate "bad" cholesterol

Johns Hopkins researchers have developed a more accurate way to calculate low-density lipoprotein (LDL) cholesterol, the so-called "bad" form of blood fat that can lead to hardening of the arteries and increase the risk of heart attack and stroke.

18 Nov 2013

New method for estimating LDL-C levels more accurate than standard measure

Seth S. Martin, M.D., of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, and colleagues developed a method for estimating low-density lipoprotein cholesterol (LDL-C) levels that is more accurate than the standard measure.

18 Nov 2013

Global Genomics Group, Metabolon partner to discover novel targets for cardiovascular diseases

Global Genomics Group and Metabolon today announced that they have entered into a collaboration agreement to investigate biological networks and pathways in order to discover novel biomarkers and pharmaceutical targets for cardiovascular diseases.

15 Nov 2013

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen, Inc. (FibroGen), today announced that data from a China-based Phase 2 study of roxadustat (FG-4592), a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), were presented in an oral session at the 2013 American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia.

13 Nov 2013

Researchers identify link between narrowed heart valves and special lipoprotein in blood

Researchers at the University of Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link between narrowed heart valves and a special lipoprotein in the blood. In the long term, the research may well help to prevent valvular heart disease.

13 Nov 2013

Academy of Nutrition and Dietetics applauds FDA’s efforts to reduce PHOs in processed foods

The Academy of Nutrition and Dietetics applauds the Food and Drug Administration's efforts, announced November 7, to reduce partially hydrogenated oils in processed foods.

8 Nov 2013

Use of testosterone therapy after angiography associated with increased risk of death

Among a group of men who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of death, heart attack, or ischemic stroke, according to a study in the November 6 issue of JAMA.

6 Nov 2013